Tianyin Pharmaceutical Co., Inc. Launches Advertising Program on China Central Television...

Tianyin Pharmaceutical Co., Inc. Launches Advertising Program on China Central
Television (CCTV) for its Xuelian Chongcao Oral Liquid
Initiative Expected to Contribute $4.4 Million in Revenues for Fiscal 2010

CHENGDU, China, June 29 /PRNewswire-Asia-FirstCall/ -- Tianyin
Pharmaceutical Co., Inc., (NYSE AMEX: TPI), a manufacturer and supplier of
modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today
announced that it has engaged a major advertising firm to commence a marketing
initiative for its Xuelian Chongcao Oral Liquid product that will include
prominent, prime-time advertisements on China Central Television (CCTV),
China's most famous television station, which is viewed by 98% of households
throughout China.
The length of the advertisements varies from 5 to 15 seconds and will run
37 to 40 times everyday for 12 months. In addition to the program on CCTV, the
advertising partner is launching an expanded TV advertising program in Shanxi,
Tianjin and Yunnan province. In the next several months, Tianyin will launch
the advertising program in various cities and provinces nationwide. Tianyin is
utilizing an innovative commission based compensation structure with this firm
that is aimed at building significant brand awareness and market share gains
while minimizing the risk to Tianyin, by placing the burden of performance on
its partner.
Tianyin received the official approval from the Chinese State Food and
Drug Administration (SFDA) to produce Xuelian Chongcao Oral Liquid in two
dosage forms, 90 ml and 150 ml back in October 2002. The retail prices of 90
ml and 150 ml are approximately $10 and $18, respectively; under typical use,
these quantities provide 3 to 5 days of treatment, respectively. Xuelian
Chongcao Oral Liquid is an Over-the-counter TCM drug that effectively
replenishes Yang due to a Yang and Qi insufficiency of the kidney, and also
improves overall energy. Tianyin will produce this product at its current
facility and management expects this product to generate revenue of
approximately $4.4 million in fiscal year 2010, with greater growth
anticipated in the following year. This revenue is a component of recently
issued guidance for fiscal 2010.
"Following in the path of our success with Ginko Mihuan, we expect Xuelian
Chongcao Oral Liquid to become a blockbuster product in our portfolio during
the next two years as we leverage this to our existing distribution network
and employ this aggressive advertising program to build brand awareness and
drive incremental sales," stated Dr. Guoqing Jiang, Tianyin's Chief Executive
Officer. "We have initiated the GMP-certification process of our new
production facility and we will immediately utilize the increased capacity for
our production needs as these marketing initiatives commence."
About Tianyin Pharmaceuticals
Tianyin is a manufacturer and supplier of modernized Traditional Chinese
Medicine ("TCM") in China. It was established in 1994 and acquired by the
current management team in August 2003. It has a comprehensive product
portfolio of 39 products, 22 of which are listed in the highly selective
National Medicine Catalog of the National Medical Insurance program. Tianyin
owns and operates two GMP manufacturing facilities and an R&D platform
supported by leading Chinese academic institutions. The Company has a pipeline
of 40 pharmaceutical products pending approval. Tianyin has an extensive
nationwide distribution network throughout China with a sales force of 720
salespeople. Tianyin is headquartered in Chengdu, Sichuan Province with two
manufacturing facilities and a total of 1,365 employees. Tianyin achieved
revenue of approximately $33.5 million and net income of approximately $6
million in FY2008 ending June 30, 2008. For more information about Tianyin,
please visit http://www.tianyinpharma.com .
Safe Harbor Statement
The Statements which are not historical facts contained in this press
release are forward-looking statements that involve certain risks and
uncertainties including but not limited to risks associated with the
uncertainty of future financial results, additional financing requirements,
development of new products, government approval processes, the impact of
competitive products or pricing, technological changes, the effect of economic
conditions and other uncertainties detailed in the Company's filings with the
Securities and Exchange Commission.
For more information, please contact:

For the Company:
Allen Tang, Ph.D., MBA, Assistant to the CEO China
Tel: +86-158-2122-5642
Email: Allen.y.tang@gmail.com

Investors:
Mr. Matthew Hayden, HC International
Tel: +1-561-245-5155
Email: matt.hayden@hcinternational.net

SOURCE Tianyin Pharmaceutical Co., Inc.

Allen Tang, Ph.D., MBA, Assistant to the CEO China at +86-158-2122-5642 or
Allen.y.tang@gmail.com; Investors: Matthew Hayden, HC International at
+1-561-245-5155 or matt.hayden@hcinternational.net